<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Deferasirox: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Deferasirox: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Deferasirox: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11527" href="/d/html/11527.html" rel="external">see "Deferasirox: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13104" href="/d/html/13104.html" rel="external">see "Deferasirox: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F9935104"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Renal failure:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Deferasirox can cause acute renal failure and death, particularly in patients with comorbidities and those who are in the advanced stages of their hematologic disorders. Evaluate baseline renal function prior to starting or increasing deferasirox dosing in all patients. Deferasirox is contraindicated in adult and pediatric patients with eGFR less than 40 mL/min/1.73 m<sup>2</sup>. Measure serum creatinine in duplicate prior to initiation of therapy. Monitor renal function at least monthly. For patients with baseline renal impairment or increased risk of acute renal failure, monitor renal function weekly for the first month, and then at least monthly. Reduce the starting dose in patients with preexisting renal disease. During therapy, increase the frequency of monitoring and modify the dose for patients with an increased risk of renal impairment, including use of concomitant nephrotoxic drugs, and pediatric patients with volume depletion or overchelation.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatic failure:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Deferasirox can cause hepatic injury, including hepatic failure and death. Measure serum transaminases and bilirubin in all patients prior to initiating treatment, every 2 weeks during the first month, and at least monthly thereafter. Avoid use of deferasirox in patients with severe (Child-Pugh class C) hepatic impairment and reduce the dose in patients with moderate (Child-Pugh class B) hepatic impairment.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Gastrointestinal hemorrhage:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Deferasirox can cause GI hemorrhages, which may be fatal, especially in elderly patients who have advanced hematologic malignancies and/or low platelet counts. Monitor patients and discontinue deferasirox for suspected GI ulceration or hemorrhage.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F1987209"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Exjade;</li>
<li>Jadenu;</li>
<li>Jadenu Sprinkle</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868713"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Deferasirox;</li>
<li>Exjade;</li>
<li>Jadenu;</li>
<li>PMS-Deferasirox;</li>
<li>PMS-Deferasirox (TYPE J);</li>
<li>SANDOZ Deferasirox;</li>
<li>Sandoz Deferasirox (Type J);</li>
<li>TARO-Deferasirox;</li>
<li>TARO-Deferasirox (Type J);</li>
<li>TEVA-Deferasirox [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F1987212"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Chelating Agent</li></ul></div>
<div class="block doa drugH1Div" id="F1987289"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Use the minimum effective dose to achieve a trend of decreasing ferritin and to maintain iron burden in the target range. Calculate dose to the nearest whole tablet size or nearest whole granules packet.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="80d05927-ff0f-4f9a-9c78-f440b8c6db5c">Chronic iron overload due to blood transfusions</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic iron overload due to blood transfusions:</b> Oral: <b>Note:</b> Treatment should only be initiated with evidence of chronic iron overload (ie, transfusion of ≥100 mL/kg of packed red blood cells [eg, ≥20 units for a 40 kg individual] and serum ferritin consistently &gt;1,000 mcg/L). Evaluate the need for ongoing therapy in patients whose conditions no longer require regular blood transfusions.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Exjade:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 20 mg/kg once daily</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance: Adjust dose every 3 to 6 months based on serum ferritin trends; adjust by 5 or 10 mg/kg/day; titrate to individual response and treatment goals. In patients not adequately controlled with 30 mg/kg/day, doses up to 40 mg/kg/day may be considered for serum ferritin levels persistently &gt;2,500 mcg/L and not decreasing over time (doses &gt;40 mg/kg/day are not recommended). If serum ferritin falls to &lt;1,000 mcg/L at 2 consecutive visits, consider dose reduction (especially if dose is &gt;25 mg/kg/day). If serum ferritin falls to &lt;500 mcg/L, interrupt therapy and continue monitoring monthly.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Jadenu:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 14 mg/kg once daily</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance: Adjust dose every 3 to 6 months based on serum ferritin trends; adjust by 3.5 or 7 mg/kg/day; titrate to individual response and treatment goals. In patients not adequately controlled with 21 mg/kg/day, doses up to 28 mg/kg/day may be considered for serum ferritin levels persistently &gt;2,500 mcg/L and not decreasing over time (doses &gt;28 mg/kg/day are not recommended). If serum ferritin falls to &lt;1,000 mcg/L at 2 consecutive visits, consider dose reduction (especially if dose is &gt;17.5 mg/kg/day). If serum ferritin falls to &lt;500 mcg/L, interrupt therapy and continue monitoring monthly.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="df809c58-2e1f-4f2c-87c6-04b4512a1c6b">Chronic iron overload in non-transfusion-dependent thalassemia syndromes</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic iron overload in non-transfusion-dependent thalassemia syndromes: </b> Oral: <b>Note:</b> Treatment should only be initiated with evidence of chronic iron overload (hepatic iron concentration ≥5 mg Fe/g dry weight and serum ferritin &gt;300 mcg/L).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Exjade:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 10 mg/kg once daily. Consider increasing to 20 mg/kg once daily after 4 weeks if baseline hepatic iron concentration is &gt;15 mg Fe/g dry weight.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance: Dependent upon serum ferritin measurements (monthly) and hepatic iron concentrations (every 6 months):</p>
<p style="text-indent:-2em;margin-left:8em;">If serum ferritin is &lt;300 mcg/L: Interrupt therapy and obtain hepatic iron concentration</p>
<p style="text-indent:-2em;margin-left:8em;">If hepatic iron concentration:</p>
<p style="text-indent:-2em;margin-left:10em;">&lt;3 mg Fe/g dry weight: Interrupt therapy; resume treatment when hepatic iron concentration is &gt;5 mg Fe/g dry weight</p>
<p style="text-indent:-2em;margin-left:10em;">3 to 7 mg Fe/g dry weight: Continue treatment at a dose of no more than 10 mg/kg/day</p>
<p style="text-indent:-2em;margin-left:10em;">&gt;7 mg Fe/g dry weight: Increase dose up to 20 mg/kg/day; Maximum dose: 20 mg/kg/day</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Jadenu:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 7 mg/kg once daily. Consider increasing to 14 mg/kg once daily after 4 weeks if baseline hepatic iron concentration is &gt;15 mg Fe/g dry weight.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance: Dependent upon serum ferritin measurements (monthly) and hepatic iron concentrations (every 6 months):</p>
<p style="text-indent:-2em;margin-left:8em;">If serum ferritin is &lt;300 mcg/L: Interrupt therapy and obtain hepatic iron concentration</p>
<p style="text-indent:-2em;margin-left:8em;">If hepatic iron concentration:</p>
<p style="text-indent:-2em;margin-left:10em;">&lt;3 mg Fe/g dry weight: Interrupt therapy; resume treatment when hepatic iron concentration is &gt;5 mg Fe/g dry weight</p>
<p style="text-indent:-2em;margin-left:10em;">3 to 7 mg Fe/g dry weight: Continue treatment at a dose of no more than 7 mg/kg/day</p>
<p style="text-indent:-2em;margin-left:10em;">&gt;7 mg Fe/g dry weight: Increase dose up to 14 mg/kg/day; Maximum dose: 14 mg/kg/day</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Conversion from Exjade to Jadenu:</b> The dose for Jadenu should be ~30% lower</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990839"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Estimated glomerular filtration rate (eGFR) should be calculated using an appropriate prediction equation (eg, CKD-EPI, MDRD method).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal impairment at treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &gt;60 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR 40 to 60 mL/minute/1.73 m<sup>2</sup>: Initial: Reduce dose by 50%.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;40 mL/minute/1.73 m<sup>2</sup>: Use is contraindicated.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Renal toxicity during treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Transfusional iron overload:</i></p>
<p style="text-indent:-2em;margin-left:6em;">For increase in serum creatinine ≥33% above the average baseline, repeat serum creatinine within 1 week; if still elevated by ≥33%: Reduce daily dose by 10 mg/kg (for Exjade) <b>or</b> 7 mg/kg (for Jadenu)</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR &lt;40 mL/minute/1.73 m<sup>2</sup>: Discontinue treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Non-transfusion-dependent thalassemia syndromes: </i></p>
<p style="text-indent:-2em;margin-left:6em;">For increase in serum creatinine ≥33% above the average baseline, repeat serum creatinine within 1 week; if still elevated by ≥33%:</p>
<p style="text-indent:-2em;margin-left:8em;">Exjade: Interrupt therapy if the dose is 5 mg/kg; reduce dose by 50% if the dose is 10 or 20 mg/kg</p>
<p style="text-indent:-2em;margin-left:8em;">Jadenu: Interrupt therapy if the dose is 3.5 mg/kg; reduce dose by 50% if the dose is 7 or 14 mg/kg</p>
<p style="text-indent:-2em;margin-left:6em;">All patients: eGFR &lt;40 mL/minute/1.73 m<sup>2</sup>: Discontinue treatment.</p></div>
<div class="block doha drugH1Div" id="F50988062"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment at treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (Child-Pugh class A): No dosage adjustment necessary; monitor closely for efficacy and for adverse reactions requiring dosage reduction.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate impairment (Child-Pugh class B): Initial: Reduce dose by 50%; monitor closely for efficacy and for adverse reactions requiring dosage reduction.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (Child-Pugh class C): Avoid use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic toxicity during treatment:</b> Severe or persistent increases in transaminases/bilirubin: Reduce dose or temporarily interrupt treatment.</p></div>
<div class="block dot drugH1Div" id="F1987293"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Auditory disturbances: Consider dose reduction or treatment interruption.</p>
<p style="text-indent:-2em;margin-left:2em;">Bone marrow suppression: Interrupt treatment; may reinitiate once cause of cytopenia has been determined; use contraindicated if platelet count &lt;50,000/mm<sup>3</sup></p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic toxicity:</p>
<p style="text-indent:-2em;margin-left:4em;">Rash (severe): Interrupt treatment; may reintroduce at a lower dose (with future dose escalation) and short-term oral corticosteroids.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe skin reaction (Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, drug reaction with eosinophilia and systemic symptoms [DRESS]): Discontinue treatment; do not reinitiate.</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Discontinue treatment for suspected GI ulceration or hemorrhage.</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity (severe): Discontinue deferasirox (and manage appropriately).</p>
<p style="text-indent:-2em;margin-left:2em;">Visual disturbance: Consider dose reduction or treatment interruption.</p></div>
<div class="block doe drugH1Div" id="F1987290"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F1987288"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13104" href="/d/html/13104.html" rel="external">see "Deferasirox: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Use the minimum effective dose to achieve a trend of decreasing ferritin and to maintain iron burden in the target range. Deferasirox is available as 2 distinct products (Exjade: Tablets for oral suspension, Jadenu: Tablets and sprinkle sachets) that are <b>not</b> bioequivalent on a mg:mg basis due to bioavailability differences. Calculate dose to the nearest whole tablet or sprinkle sachet size.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="70b0aa8a-7a95-415f-95fd-6720d9d0ac01">Blood transfusion; chronic iron overload</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Blood transfusion; chronic iron overload:</b>
<b>Note:</b> Treatment should only be initiated with evidence of chronic iron overload (ie, transfusion of ≥100 mL/kg of packed RBCs [eg, ≥20 units for a 40 kg individual] and serum ferritin consistently &gt;1,000 mcg/L). Evaluate the need for ongoing therapy in patients whose conditions no longer require regular blood transfusions.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Exjade (oral tablet for suspension)</i>: Children ≥2 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 20 mg/kg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Titration and maintenance: Adjust dose every 3 to 6 months based on serum ferritin levels; increase dose by 5 or 10 mg/kg/day increments; usual range: 20 to 30 mg/kg/day; for serum ferritin levels persistently &gt;2,500 mcg/L without evidence of a decreasing trend, may consider a dose of 40 mg/kg/day; doses &gt;40 mg/kg/day are not recommended.</p>
<p style="text-indent:-2em;margin-left:6em;">Dosing adjustments:</p>
<p style="text-indent:-2em;margin-left:8em;">If the serum ferritin &lt;1,000 mcg/L at 2 consecutive visits: Consider dose reduction, particularly if dose is &gt;25 mg/kg/day.</p>
<p style="text-indent:-2em;margin-left:8em;">If serum ferritin is &lt;500 mcg/L: Interrupt therapy; continue to monitor monthly.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Jadenu (oral tablet; sprinkle granules)</i>: Children ≥2 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 14 mg/kg once daily, calculate dose to the nearest whole tablet or sprinkle sachet.</p>
<p style="text-indent:-2em;margin-left:6em;">Titration and maintenance: Adjust dose every 3 to 6 months based on serum ferritin trends; adjust by 3.5 or 7 mg/kg/day; titrate to individual response and treatment goals. In patients not adequately controlled at a dose of 21 mg/kg/day (eg, serum ferritin levels persistently &gt;2,500 mcg/L and not decreasing over time), then higher doses up to 28 mg/kg/day may be considered; doses &gt;28 mg/kg/day are not recommended).</p>
<p style="text-indent:-2em;margin-left:6em;">Dosing adjustment:</p>
<p style="text-indent:-2em;margin-left:8em;">If the serum ferritin &lt;1,000 mcg/L at 2 consecutive visits: Consider dose reduction, particularly if dose is &gt;17.5 mg/kg/day.</p>
<p style="text-indent:-2em;margin-left:8em;">If serum ferritin &lt;500 mcg/L: Interrupt therapy; continue to monitor monthly.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="922bd10d-567b-4f35-aad1-4ebec94e547c">Nontransfusion-dependent chronic iron overload; thalassemia syndromes</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nontransfusion-dependent chronic iron overload; thalassemia syndromes (NTDT):</b>
<b>Note:</b> Treatment should only be initiated with evidence of chronic iron overload (liver iron concentration [LIC] ≥5 mg Fe/g dry weight and serum ferritin &gt;300 mcg/L).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Exjade (oral tablet for suspension)</i>: Children ≥10 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 10 mg/kg once daily; after 4 weeks, if baseline hepatic iron concentration was &gt;15 mg Fe/g dry weight, may increase to 20 mg/kg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance: Dependent upon serum ferritin measurements (monthly) and LIC (every 6 months).</p>
<p style="text-indent:-2em;margin-left:8em;">If serum ferritin is &lt;300 mcg/L: Interrupt therapy and obtain LIC.</p>
<p style="text-indent:-2em;margin-left:8em;">If LIC:</p>
<p style="text-indent:-2em;margin-left:10em;">&lt;3 mg Fe/g dry weight: Interrupt therapy; resume treatment when LIC is &gt;5 mg Fe/g dry weight.</p>
<p style="text-indent:-2em;margin-left:10em;">3 to 7 mg Fe/g dry weight: Continue treatment at a dose ≤10 mg/kg/day.</p>
<p style="text-indent:-2em;margin-left:10em;">&gt;7 mg Fe/g dry weight: Increase dose to 20 mg/kg/day if not already; maximum daily dose: 20 mg/kg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Jadenu (oral tablet, sprinkle granules):</i> Children ≥10 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 7 mg/kg once daily; after 4 weeks, if hepatic iron concentration was &gt;15 mg Fe/g dry weight, may increase to 14 mg/kg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance: Dependent upon serum ferritin measurements (monthly) and LIC (every 6 months).</p>
<p style="text-indent:-2em;margin-left:8em;">If serum ferritin is &lt;300 mcg/L: Interrupt therapy and obtain LIC.</p>
<p style="text-indent:-2em;margin-left:8em;">If LIC:</p>
<p style="text-indent:-2em;margin-left:10em;">&lt;3 mg Fe/g dry weight: Interrupt therapy; resume treatment when LIC is &gt;5 mg Fe/g dry weight.</p>
<p style="text-indent:-2em;margin-left:10em;">3 to 7 mg Fe/g dry weight: Continue treatment at a dose ≤7 mg/kg/day.</p>
<p style="text-indent:-2em;margin-left:10em;">&gt;7 mg Fe/g dry weight: Increase dose to 14 mg/kg/day if not already; maximum daily dose: 14 mg/kg/<b>day</b>.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing</b>
<b> conversion from Exjade to Jadenu:</b> The dose for Jadenu should be ~30% lower than Exjade (doses rounded to the nearest whole tablet or sachet).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity: </b>Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Auditory disturbances: Consider dose reduction or treatment interruption.</p>
<p style="text-indent:-2em;margin-left:4em;">Bone marrow suppression: Interrupt treatment; may reinitiate once cause of cytopenia has been determined; contraindicated if platelet count &lt;50,000/mm<sup>3</sup>.</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic toxicity:</p>
<p style="text-indent:-2em;margin-left:6em;">Rash (severe): Interrupt treatment; may reintroduce at a lower dose (with future dose escalation) and short-term oral corticosteroids.</p>
<p style="text-indent:-2em;margin-left:6em;">Severe skin reaction (Stevens-Johnson syndrome, erythema multiforme): Discontinue treatment; do not reinitiate.</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Discontinue treatment for suspected GI ulceration or hemorrhage.</p>
<p style="text-indent:-2em;margin-left:4em;">Hearing loss or visual disturbance: Consider dose reduction or treatment interruption.</p></div>
<div class="block dorp drugH1Div" id="F51090535"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Baseline:</i> Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &gt;60 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR 40 to 60 mL/minute/1.73 m<sup>2</sup>: Reduce initial dose by 50%; use with caution; treat with the minimum effective dose and monitor frequently</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;40 mL/minute/1.73 m<sup>2</sup>: Use is contraindicated</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>During therapy:</i> Adjustment dependent upon indication for use.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transfusional iron overload: </b></p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥2 years and Adolescents ≤17 years: For decrease in the eGFR by ≥33% below the average baseline level: Reduce daily dose <b>by</b> 10 mg/kg/day (for Exjade) or 7 mg/kg (for Jadenu); repeat eGFR within 1 week</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Interrupt deferasirox therapy for any acute illness that may result in volume depletion including vomiting, diarrhea, or prolonged decreased oral intake; monitor renal function and fluid status frequently and correct fluid deficits; may resume therapy based on volume status, renal function, and oral intake as appropriate.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥18 years: If increase in serum creatinine ≥33% above the average baseline: Repeat serum creatinine measurement in 1 week; if still elevated by ≥33%: Reduce daily dose <b>by</b> 10 mg/kg/day (for Exjade) or 7 mg/kg (for Jadenu)</p>
<p style="text-indent:-2em;margin-left:6em;">All patients: eGFR &lt;40 mL/minute/1.73 m<sup>2</sup>: Discontinue therapy; use is contraindicated</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Nontransfusion-dependent thalassemia syndromes (NTDT): </b></p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥10 years and Adolescents ≤17 years: For decrease in eGFR ≥33% below the average baseline level: Reduce daily dose <b>by</b> 5 mg/kg/day (for Exjade) or 3.5 mg/kg (for Jadenu); repeat eGFR within 1 week</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> For acute illness which may cause volume depletion, increase monitoring frequency and consider dose interruption until oral intake and volume status are normal.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥18 years: If increase in serum creatinine ≥33% above the average baseline; repeat serum creatinine measurement in 1 week; if still elevated <b>by</b> ≥33%:</p>
<p style="text-indent:-2em;margin-left:8em;">Exjade: Interrupt therapy if the dose is 5 mg/kg; reduce dose <b>by</b> 50% if the dose is 10 or 20 mg/kg</p>
<p style="text-indent:-2em;margin-left:8em;">Jadenu: Interrupt therapy if the dose is 3.5 mg/kg; reduce dose <b>by</b> 50% if the dose is 7 or 14 mg/kg</p>
<p style="text-indent:-2em;margin-left:6em;">All patients: If eGFR &lt;40 mL/minute/1.73 m<sup>2</sup>: Discontinue therapy; use is contraindicated</p></div>
<div class="block dohp drugH1Div" id="F51090536"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Baseline:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Mild impairment: No adjustment necessary; monitor closely for efficacy and for adverse reactions requiring dosage reduction</p>
<p style="text-indent:-2em;margin-left:6em;">Moderate impairment: Reduce initial dose <b>by</b> 50%; monitor closely for efficacy and for adverse reactions requiring dosage reduction</p>
<p style="text-indent:-2em;margin-left:6em;">Severe impairment: Avoid use</p>
<p style="text-indent:-2em;margin-left:4em;">
<i> During therapy:</i> Severe or persistent increases in transaminases/bilirubin: Reduce dose or temporarily interrupt treatment</p></div>
<div class="block adr drugH1Div" id="F1987242"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (6% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (21% to 28%), diarrhea (5% to 20%), nausea (6% to 23%), vomiting (10% to 21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Proteinuria (19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (7% to 11%; increase &gt;33% from baseline at 2 consecutive visits: 3% to 38%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dyschromia</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Fanconi’s syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Acute pancreatitis, cholelithiasis, duodenal ulcer, gastric ulcer, gastritis, gastrointestinal hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (&gt;5 x ULN: 1% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, dizziness, fatigue, sleep disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Cataract, maculopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Hearing loss (including high frequency)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal tubular disease</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pharyngolaryngeal pain</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Esophagitis</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Increased intraocular pressure, optic neuritis, retinopathy</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Glycosuria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (Vichinsky 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic: Henoch-Schönlein purpura</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis, increased serum bilirubin (Vichinsky 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Atypical mycobacterial infection, infection, viral infection (Vichinsky 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drug fever, headache (Phatak 2010; Vichinsky 2007), hyperactive behavior, insomnia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (Vichinsky 2007), back pain (Vichinsky 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (Vichinsky 2007), nasopharyngitis (Vichinsky 2007), pharyngitis (Vichinsky 2007), respiratory tract infection (Vichinsky 2007)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypersensitivity angiitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastrointestinal perforation</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, anemia (worsening), neutropenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury, interstitial nephritis</p></div>
<div class="block coi drugH1Div" id="F1987218"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Known hypersensitivity to deferasirox or any component of the formulation; eGFR &lt;40 mL/minute/1.73 m<sup>2</sup>; poor performance status; high-risk myelodysplastic syndromes; advanced malignancies; platelet counts &lt;50,000/mm<sup>3</sup></p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): MDS patients with &lt;1 year life expectancy; CrCl &lt;60 mL/minute; patients with other hematological and nonhematological malignancies who are not expected to benefit from chelation therapy (due to rapid progression of their disease)</p></div>
<div class="block war drugH1Div" id="F1987219"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Auditory disturbances: Decreased hearing and high-frequency hearing loss have been reported (rare) with deferasirox; perform auditory testing prior to initiation and regularly (every 12 months) during use; if abnormalities develop, monitor more closely and consider dose reduction or treatment interruption. Although causality is not established, auditory adverse events may be more frequent among pediatric patients receiving doses &gt;25 mg/kg/day (Exjade) or &gt;17.5 mg/kg/day (Jadenu) when serum ferritin is &lt;1,000 mcg/L.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Cytopenias (including agranulocytosis, neutropenia, thrombocytopenia, and worsening anemia) have been reported (some fatal); risk may be increased in patients with preexisting hematologic disorders; monitor blood counts regularly. Interrupt treatment in patients who develop cytopenias; may reinitiate once cause of cytopenia has been determined; use contraindicated if platelet count &lt;50,000/mm<sup>3</sup>.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic toxicity: May cause skin rash (dose-related); mild to moderate rashes may resolve without treatment interruption; for severe rash, interrupt and consider restarting at a lower dose with dose escalation and oral steroids. Severe and potentially life-threatening skin reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis, erythema multiforme, and drug reaction with eosinophilia and systemic symptoms (DRESS), have also been reported. If severe skin reactions are suspected, discontinue immediately and evaluate; do not reintroduce therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal reactions: <b>[US Boxed Warning]: GI hemorrhages (including fatalities) may occur; observed more frequently in elderly patients with advanced hematologic malignancies and/or low platelet counts; discontinue treatment for suspected GI hemorrhage or ulceration. </b>Nonfatal upper GI irritation, hemorrhage, and ulceration (sometimes complicated with GI perforation, including fatalities) have been reported. Use caution with concurrent medications that may increase risk of adverse GI effects (eg, NSAIDs, corticosteroids, anticoagulants, oral bisphosphonates). Monitor patients closely for signs/symptoms of GI ulceration/bleeding.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic failure: <b>[US Boxed Warning]: Hepatic injury and failure (including fatalities) may occur. Monitor transaminases and bilirubin at baseline, every 2 weeks for 1 month, then at least monthly thereafter. </b>
<b>Avoid use in patients with severe (Child-Pugh class C) hepatic impairment; initial dose reduction is required in patients with moderate (Child-Pugh class B) hepatic impairment. </b>Patients with mild (Child-Pugh class A) or moderate (Child-Pugh class B) impairment may have a higher risk for toxicities. Hepatotoxicity may be more common in patients &gt;55 years. Patients with significant comorbidities (eg, liver cirrhosis and multiorgan failure) may experience hepatic failure more commonly. Acute liver injury and failure, including fatal outcomes, have occurred in pediatric patients. Hepatic failure associated with acute kidney injury has occurred in pediatric patients at risk for overchelation during states of volume depletion. Interrupt treatment if acute liver injury or acute kidney injury are suspected, and during volume depletion<i>. </i>Monitor liver and renal function more frequently in pediatric patients who are receiving 20 to 40 mg/kg/day (Exjade) or 14 to 28 mg/kg/day (Jadenu) when iron burden is approaching normal. Use the minimum effective dose to achieve and maintain a low iron burden. Monitor liver function tests (ALT, AST, and bilirubin) prior to treatment initiation, every 2 weeks during the first month, and monthly thereafter; consider dose reduction or treatment interruption for severe or persistent elevations.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions, including severe reactions (anaphylaxis and angioedema) have been reported; onset is usually within the first month of treatment. Discontinue if reaction is severe and do not reintroduce patients with previous hypersensitivity reactions due to risk of anaphylactic shock.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular disturbances: Lens opacities, cataracts, intraocular pressure elevation, and retinal disorders have been reported (rare) with use; perform ophthalmic testing prior to initiation and regularly (every 12 months) during use; if abnormalities develop, monitor more closely and consider dose reduction or treatment interruption.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal failure: <b>[US Boxed Warning]: </b>
<b>Deferasirox may cause acute renal failure and death, particularly in patients with comorbidities and those who are in the advanced stages of their hematologic disorders. Evaluate renal function in all patients at baseline and prior to deferasirox dose increases. Deferasirox is contraindicated in adult and pediatric patients with eGFR &lt;40 mL/min/1.73 m<sup>2</sup>. Monitor serum creatinine in duplicate prior to treatment initiation and at least monthly. For patients with baseline renal impairment or increased risk of acute renal failure, monitor renal function weekly for the first month, and then at least monthly. Reduce the starting dose in patients with preexisting renal disease. Increase the monitoring frequency during treatment and modify the dose for patients with an increased risk of renal impairment, including use of concomitant nephrotoxic drugs, and pediatric patients with volume depletion or overchelation. </b>Monitor serum creatinine and/or eGFR more frequently if creatinine levels are increasing. Use the minimum effective dose necessary to establish and maintain a low iron burden and monitor renal function frequently. Individualize dose titration based on improvement in renal injury. Initial dose reductions are required in patients with renal impairment (eGFR 40 to 60 mL/min/1.73 m<sup>2</sup>); use with caution in pediatric patients with eGFR of 40 to 60 mL/minute/1.73 m<sup>2</sup>. Deferasirox may cause acute kidney injury including renal failure requiring dialysis (with fatal outcomes); based on postmarketing experience, most fatalities have occurred in patients with multiple comorbidities and who were in advanced stages of hematological disorders. In studies, deferasirox-treated patients with no preexisting renal disease experienced dose-dependent mild, nonprogressive increases in serum creatinine and proteinuria. Preexisting renal disease and concomitant use of other nephrotoxic drugs may increase the risk of acute kidney injury. Acute illnesses associated with volume depletion and overchelation may increase the risk of acute kidney injury in pediatric patients. In pediatric patients, small decreases in eGFR may result in increased deferasirox exposure, particularly in younger patients (&lt;7 years of age); without dose reduction or treatment interruption, may result in worsening renal function and further increases in deferasirox exposure. Renal tubular toxicity, including acquired Fanconi Syndrome, has been reported, most commonly in pediatric patients with beta-thalassemia and serum ferritin levels &lt;1,500 mcg/L. Evaluate renal glomerular and tubular function prior to treatment initiation and dose increases. Monitor electrolytes and urinalysis to evaluate renal tubular function. Monitor all patients for changes in eGFR and for renal tubular toxicity weekly during the first treatment month, after treatment modifications, and at least monthly thereafter; consider dosage reduction or interruption of therapy in patients with abnormalities in levels of markers of renal tubular function or if clinically indicated. Monitor serum ferritin monthly (to evaluate for overchelation). Monitor renal function more frequently in patients with preexisting renal disease or decreased renal function. Interrupt treatment and monitor renal function more frequently in pediatric patients during acute illnesses resulting in volume depletion (eg, diarrhea, vomiting, or prolonged decreased oral intake); to prevent renal injury, promptly correct fluid deficits; resume treatment as appropriate when oral intake and volume status are normal (based on renal function assessment).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution due to the higher incidence of toxicity (eg, hepatotoxicity) and fatal reactions during use; monitor elderly patients closely.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatrics: Deferasirox is associated with serious and fatal adverse reactions in pediatric patients, usually associated with volume depletion or with continued doses of 20 to 40 mg/kg/day (Exjade) or 14 to 28 mg/kg/day (Jadenu) when body iron burden was approaching or in the normal range. Interrupt treatment in pediatric patients with transfusional iron overload with acute illnesses which may cause volume depletion (eg, diarrhea, vomiting, prolonged decreased oral intake) and monitor more frequently; resume treatment as appropriate based on renal function assessment and when oral intake and volume status are normal. For patients with non-transfusion-dependent thalassemia (NTDT) syndromes with acute illness which may cause volume depletion, increase monitoring frequency and consider dose interruption until oral intake and volume status are normal. Monitor liver and renal function more frequently during volume depletion and in patients receiving doses of 20 to 40 mg/kg/day (Exjade) or 14 to 28 mg/kg/day (Jadenu) when iron burden is approaching the normal range. Use the minimum effective dose to achieve and maintain a low iron burden.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Lactose: Some formulations may contain lactose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Other minerals: Deferasirox has a low affinity for binding with zinc and copper, may cause variable decreases in the serum concentration of these trace minerals.</p>
<p style="text-indent:-2em;margin-left:4em;">• Overchelation: Overchelation of iron may increase development of renal toxicity with doses &gt;25 mg/kg/day (Exjade) or &gt;17.5 mg/kg/day (Jadenu) while serum ferritin values &lt;1,000 mcg/L. If the serum ferritin falls below 1,000 mcg/L at 2 consecutive visits, consider dose reduction (particularly if the dose is &gt;25 mg/kg/day [Exjade] or &gt;17.5 mg/kg/day [Jadenu]). If the serum ferritin falls to &lt;500 mcg/L, interrupt therapy and continue monthly monitoring. Evaluate the need for ongoing chelation in patients who do not require regular blood transfusions. Use the minimum effective dose to maintain iron burden in the target range. Continued administration of doses of 20 to 40 mg/kg/day (Exjade) or 14 to 28 mg/kg/day (Jadenu) when the body iron burden is approaching or within the normal range is associated with life-threatening adverse reactions. For patients with NTDT, measure liver iron concentration (LIC) (by liver biopsy or appropriate monitoring method) every 6 months during therapy. Interrupt deferasirox treatment when LIC &lt;3 mg Fe/g dry weight. Monitor serum ferritin monthly to assess response to therapy and minimize risk of overchelation; if serum ferritin falls to &lt;300 mcg/L, interrupt deferasirox treatment and obtain confirmatory LIC</p></div>
<div class="block foc drugH1Div" id="F1987300"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Packet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Jadenu Sprinkle: 90 mg (1 ea, 30 ea); 180 mg (1 ea, 30 ea); 360 mg (1 ea, 30 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 90 mg (1 ea, 30 ea); 180 mg (1 ea, 30 ea); 360 mg (1 ea, 30 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Jadenu: 90 mg, 180 mg, 360 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 90 mg, 180 mg, 360 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Soluble, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Exjade: 125 mg, 250 mg, 500 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 125 mg, 250 mg, 500 mg</p></div>
<div class="block geq drugH1Div" id="F1988061"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16322889"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Deferasirox Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">90 mg (per each): $45.56 - $47.88</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">180 mg (per each): $91.11 - $95.76</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">360 mg (per each): $182.22 - $191.52</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Jadenu Sprinkle Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">90 mg (per each): $60.23</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">180 mg (per each): $120.44</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">360 mg (per each): $240.92</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet,Dispersible</b> (Deferasirox Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mg (per each): $28.16 - $48.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $56.32 - $96.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $112.64 - $192.55</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet,Dispersible</b> (Exjade Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mg (per each): $60.23</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $120.46</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $240.91</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Deferasirox Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">90 mg (per each): $43.07 - $47.51</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">180 mg (per each): $91.11 - $96.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">360 mg (per each): $172.28 - $190.02</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Jadenu Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">90 mg (per each): $60.23</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">180 mg (per each): $120.46</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">360 mg (per each): $240.91</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868714"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Jadenu: 90 mg, 180 mg, 360 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 90 mg, 180 mg, 360 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Soluble, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Exjade: 125 mg, 250 mg, 500 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 125 mg, 250 mg, 500 mg</p></div>
<div class="block adm drugH1Div" id="F1987294"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral:</p>
<p style="text-indent:-2em;margin-left:2em;">Do not take simultaneously with aluminum-containing antacids.</p>
<p style="text-indent:-2em;margin-left:2em;">Granules (Jadenu): Administer on an empty stomach or with a light meal, at the same time each day. Sprinkle granules on soft food (eg, yogurt or applesauce) immediately prior to administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets (Jadenu): Swallow with water or other liquids at the same time each day. Administer on an empty stomach or with a light meal (contains &lt;7% fat content and ~250 calories). For patients who have difficulty swallowing whole tablets, may crush tablets and mix with soft foods (eg, yogurt, applesauce); consume entire mixture immediately after preparation (do not store for future use). Commercial crushers with serrated surfaces should be avoided for crushing a single 90 mg tablet.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets for suspension (Exjade): Administer tablets by making an oral suspension; <b>do not chew or swallow tablets whole.</b> Completely disperse tablets in water, orange juice, or apple juice (use 105 mL for total doses &lt;1 g; 210 mL for doses ≥1 g); stir to form a fine suspension and drink entire contents. Rinse remaining residue with more fluid; drink. Avoid dispersion of tablets in milk (due to slowed dissolution) or carbonated drinks (due to foaming) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18218291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18218291'])">Ref</a></span>). Administer at same time each day on an empty stomach, at least 30 minutes before food.</p></div>
<div class="block admp drugH1Div" id="F52614170"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral:</p>
<p style="text-indent:-2em;margin-left:2em;">Granules (Jadenu): Sprinkle granules on soft food (eg, yogurt or applesauce) immediately prior to administration. Administer on an empty stomach or with a light meal (containing less than 7% fat content and ~250 calories) at the same time each day. Do not administer simultaneously with aluminum-containing antacids.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets (Jadenu): Administer with water or other liquids at the same time each day. Administer on an empty stomach or with a light meal (containing less than 7% fat content and ~250 calories). Do not administer simultaneously with aluminum-containing antacids. Commercial crushers with serrated surfaces should be avoided for crushing a single 90 mg tablet.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets for oral suspension (Exjade): Administer tablets by making an oral suspension; <b>do not chew or swallow whole tablets</b>. Stir to form suspension and drink entire contents. Rinse remaining residue with more fluid; drink. Administer at same time each day on an empty stomach, at least 30 minutes before food. Do not administer simultaneously with aluminum-containing antacids.</p></div>
<div class="block meg drugH1Div" id="F53483010"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Exjade: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2020%2F021882s033lbl.pdf%23page%3D28&amp;token=pE7h%2FXsBQo%2F721Hl1Nf8U%2B7TK%2BLI9c8MTENxuBd8HN77luPBe1HagiEuRBpkQLIVCQsY%2BJc2o6l%2BgqT%2FQNZ%2FxZioJDOHsNQc%2BoJckWMeTctQonv4HtzrrHHJ%2B%2FUcTSJ%2B&amp;TOPIC_ID=8794" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021882s033lbl.pdf#page=28</a></p>
<p style="text-indent:-2em;margin-left:4em;">Jadenu: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2020%2F207968s009lbl.pdf%23page%3D31&amp;token=QtcsCeVrAEHwrMtOQLJ0YN7T7wv1fvGZOwHQAiQaMiFE1EANv8yCxpcHuuYJEVLHgeJBW8d5jQsrQ%2FgNWjokMLR5kZWL9voiShHxTiHmjYo1814e%2FVNHurJ21Sm1pBrX&amp;TOPIC_ID=8794" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/207968s009lbl.pdf#page=31</a></p></div>
<div class="block use drugH1Div" id="F1987214"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic iron overload due to blood transfusions:</b> Treatment of chronic iron overload caused by blood transfusions (transfusional hemosiderosis) in patients ≥2 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic iron overload in non-transfusion-dependent thalassemia syndromes:</b> Treatment of chronic iron overload in patients ≥10 years of age with non-transfusion-dependent thalassemia syndromes and with a liver iron concentration of at least 5 mg of iron per gram of liver dry weight (mg Fe/g dry weight) and a serum ferritin &gt;300 mcg/L.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Safety and efficacy of deferasirox in combination with other iron chelation therapies have not been established.</p></div>
<div class="block mst drugH1Div" id="F4432943"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Deferasirox may be confused with deferiprone, deferoxamine.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F9935524"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of UGT1A1; <b>Inhibits</b> CYP1A2 (moderate), CYP2C8 (moderate)</p></div>
<div class="block dri drugH1Div" id="F1987249"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Agomelatine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Agomelatine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alosetron: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Alosetron.  Management: Avoid concomitant use of alosetron and moderate CYP1A2 inhibitors whenever possible. If combined use is necessary, monitor for increased alosetron effects/toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aluminum Hydroxide: May diminish the therapeutic effect of Deferasirox.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amodiaquine: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Amodiaquine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: CYP1A2 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Anagrelide. CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Anagrelide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: May enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bendamustine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Bendamustine.  Management: Consider alternatives to moderate CYP1A2 inhibitors during therapy with bendamustine due to the potential for increased bendamustine plasma concentrations and increased bendamustine toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betibeglogene Autotemcel: Iron Chelators may diminish the therapeutic effect of Betibeglogene Autotemcel.  Management: Avoid use of iron chelators for at least 7 days prior to conditioning therapy preceding betibeglogene autotemcel treatment, and avoid use of myelosuppressive iron chelators for at least 6 months after betibeglogene autotemcel.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the serum concentration of Deferasirox. Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisphosphonate Derivatives: May enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromazepam: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Bromazepam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Busulfan: Deferasirox may increase the serum concentration of Busulfan.  Management: Discontinue deferasirox 2 to 3 days (approximately 5 half-lives) before initiation of busulfan. If combined, monitor for increased busulfan concentrations and effects. Decreased busulfan doses may be required during concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caffeine and Caffeine Containing Products: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Caffeine and Caffeine Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ClomiPRAMINE: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of ClomiPRAMINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers): Deferasirox may decrease the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Dabrafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daprodustat: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Daprodustat.  Management: Reduce the daprodustat starting dose by half if combined with moderate CYP2C8 inhibitors, unless the dose is 1 mg, then no dose adjustment is required. Monitor hemoglobin and adjust daprodustat dose when starting or stopping moderate CYP2C8 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasabuvir: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Dasabuvir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desloratadine: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Desloratadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enzalutamide: CYP2C8 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Enzalutamide. CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Enzalutamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Exagamglogene Autotemcel: Iron Chelators may enhance the myelosuppressive effect of Exagamglogene Autotemcel. Iron Chelators may diminish the therapeutic effect of Exagamglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fezolinetant: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Fezolinetant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovotibeglogene Autotemcel: Iron Chelators may enhance the myelosuppressive effect of Lovotibeglogene Autotemcel. Iron Chelators may diminish the therapeutic effect of Lovotibeglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Melatonin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: May decrease the serum concentration of UGT1A1 Substrates.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May decrease the serum concentration of Deferasirox.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of OLANZapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir. Specifically, the concentrations of the dasabuvir component may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: CYP2C8 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Ozanimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Conventional): CYP2C8 Inhibitors (Moderate) may increase the serum concentration of PACLitaxel (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Protein Bound): CYP2C8 Inhibitors (Moderate) may increase the serum concentration of PACLitaxel (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pentoxifylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pioglitazone: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Pioglitazone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: Avoid concomitant use of pirfenidone and moderate CYP1A2 inhibitors whenever possible. If combined, decrease the pirfenidone dose to 1,602 mg per day (534 mg three times daily) and monitor for increased pirfenidone toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pomalidomide: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pomalidomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propranolol: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Propranolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramelteon: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Ramelteon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rasagiline: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Rasagiline.  Management: Limit rasagiline dose to 0.5 mg once daily in patients taking moderate CYP1A2 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repaglinide: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Repaglinide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPivacaine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of ROPivacaine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selexipag: CYP2C8 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Selexipag.  Management: Reduce the selexipag dose to once daily when combined with moderate CYP2C8 inhibitors. Revert back to twice daily selexipag dosing upon stopping the moderate CYP2C8 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tasimelteon: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Tasimelteon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Theophylline Derivatives.  Management: Consider avoidance of this combination. If coadministration is necessary, monitor for increased theophylline serum concentrations and toxicities when combined. Theophylline dose reductions will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">TiZANidine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of TiZANidine.  Management: If combined use cannot be avoided, initiate tizanidine in adults at 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Treprostinil: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Treprostinil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tucatinib: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Tucatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">UGT1A1 Inducers: May decrease the serum concentration of Deferasirox. Management: Avoid concomitant use of deferasirox and UGT1A1 inducers when possible. If combined, consider a 50% increase in the initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical response to guide further dosing.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F13842282"><span class="drugH1">Food Interactions</span>
<p style="text-indent:-2em;margin-left:2em;">Tablets for oral suspension: Bioavailability is increased variably when taken with food. Management: Take on an empty stomach at the same time each day at least 30 minutes before food. Maintain adequate hydration, unless instructed to restrict fluid intake.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets: Bioavailability decreased slightly (not clinically meaningful) after a low-fat meal and increased after a high-fat meal. Management: Take on an empty stomach or with a light meal (containing ~250 calories and &lt;7% fat content).</p></div>
<div class="block rep_considerations drugH1Div" id="F53563391"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Infertility associated with beta-thalassemia may be reversible following deferasirox therapy (Anastasi 2011). Use of hormonal contraceptives may be ineffective in preventing pregnancy; nonhormonal contraception is recommended during deferasirox therapy.</p></div>
<div class="block pri drugH1Div" id="F1987216"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Information related to the use of deferasirox in pregnant women is limited and, in some cases, treatment was discontinued once pregnancy was discovered (Anastasi 2011; Diamantidis 2016; Fozza 2017; Ricchi 2011; Vini 2011).</p></div>
<div class="block brc drugH1Div" id="F13315456"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if deferasirox is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox was not detected in the breast milk of one woman 2 hours after a dose; adverse events were not observed in her exclusively breastfed infant. Maternal dosing started 1 week after delivery and infant monitoring continued for 30 days (Giampreti 2018). Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends a decision be made to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>
<div class="block dic drugH1Div" id="F1987253"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Tablets for oral suspension: Bioavailability increased variably when taken with food; take on empty stomach 30 minutes before a meal.</p>
<p style="text-indent:-2em;margin-left:2em;">Granules and Tablets: Bioavailability decreased slightly (not clinically meaningful) after a low-fat meal and increased after a high fat meal; take on an empty stomach or with a light meal (containing ~250 calories and &lt;7% fat content).</p></div>
<div class="block mop drugH1Div" id="F1987296"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Transfusional iron overload:</b> Serum ferritin (baseline, monthly thereafter, and with dose increases), CBC with differential (monthly), serum electrolytes (baseline and with dose increases), renal function including serum creatinine (in duplicate at baseline), and eGFR (baseline); monitor weekly during the first month after initiation or modification of therapy and then monthly thereafter and with dose increases; liver function including serum transaminases (ALT/AST) and bilirubin (baseline, every 2 weeks for the first month, then at least monthly, and with dose increases); urinalysis (baseline and with dose increases), including urine protein (monthly); monitor cumulative number of RBC units received.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-transfusion-dependent thalassemia syndromes:</b> Liver iron concentration (either by biopsy or other approved method; baseline, then every 6 months and as clinically indicated); serum ferritin (at least 2 measurements 1 month apart prior to treatment and then monthly), CBC with differential (monthly), serum electrolytes (baseline and with dose increases); renal function including serum creatinine (in duplicate at baseline), and eGFR (baseline); monitor weekly during the first month after initiation or modification of therapy and then monthly thereafter and with dose increases; serum transaminases (ALT/AST) and bilirubin (baseline, every 2 weeks for the first month, and then at least monthly and with dose increases); urinalysis (baseline and with dose increases).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>All patients:</b> Monitor blood glucose more frequently in patients with diabetes. Auditory examination (baseline, annually, and prior to dose increases); ophthalmic examination (including slit lamp examinations and dilated fundoscopy; baseline, annually, and prior to dose increases). Monitor for changes in eGFR and for signs of renal tubular toxicity weekly during the first month; monitor liver function and renal function more frequently in pediatric patients receiving doses of 20 to 40 mg/kg/day (Exjade) or 14 to 28 mg/kg/day (Jadenu) and when iron burden is approaching normal. Monitor for toxicities more frequently in elderly patients, in pediatric patients experiencing volume depletion or overchelation, and in patients receiving concomitant nephrotoxic drugs. Monitor for signs/symptoms of dermatologic toxicity, GI ulcers, hemorrhage, and /or hypersensitivity.</p></div>
<div class="block pha drugH1Div" id="F1987256"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Deferasirox is an iron chelating agent that selectively binds iron, forming a complex that is excreted primarily through the feces.</p></div>
<div class="block phk drugH1Div" id="F1987259"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Adults: 14.37 ± 2.69 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~99% to serum albumin</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via glucuronidation by UGT1A1 (primarily) and UGT1A3; minor oxidation by CYP450; undergoes enterohepatic recirculation</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Tablets for oral suspension: 70%; Tablets: 36% greater than tablets for oral suspension; Granules: 52% greater than tablets for oral suspension</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 8 to 16 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Tablets and tablets for oral suspension: ~1.5 to 4 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (84%); urine (8%)</p></div>
<div class="block phksp drugH1Div" id="F51220929"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Patients (pediatric and adult) with myelodysplastic syndromes (MDS) and eGFR 40 to 60 mL/minute/1.73 m<sup>2</sup> had ~50% higher mean deferasirox trough levels compared to patients with MDS and eGFR &gt;60 mL/minute/1.73 m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: In a single dose (20 mg/kg) study deferasirox exposure was increased in patients with hepatic impairment compared to patients with normal hepatic function. The average total (free and bound) AUC increased 16% in patients with mild (Child-Pugh class A) impairment and increased 76% in patients with moderate (Child-Pugh class B) impairment, compared to patients with normal hepatic function.</p>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: Systemic exposure has been shown to be less in pediatric patients (2 to 16 years) compared to adults; in children 2 to 6 years, exposure was reduced by ~50% compared to adults; however, results of safety and efficacy trials using the same dose were similar in pediatric and adult patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: Clearance is moderately lower (by 17.5%) in females compared to males.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539963"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Exjade | Jadenu</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Deferade | Exjade | Fesirox | Jadenu | Roxifer</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Deferasirox accord | Deferasirox g.l. | Deferasirox ratiopharm | Deferasirox stada | Exjade</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">DEFERACIP | Deferasirox arx | Deferasirox juno | Deferasirox sandoz | Deferasirox teva | Eferas | Exjade</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Asunra | Ferasirrox</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Deferasirox accord | Exjade | Ferupantil</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Deferasirox accord | Deferasirox mylan | Deferasirox pharmascience | Deferasirox stada | Exjade | Ferupantil | Zeoks | Ziadex</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Desairon | Exjade | Ezafer | Syderotelos</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Deferasirox accord | Deferasirox mepha | Deferasirox nobel | Exjade | Jadenu</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Asunra</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Exjade | Jadenu</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Exjade | Ferasiro | Ferrinova | Jadenu | Jedoxred | Rasirox</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Deferasirox accord | Deferasirox glenmark | Deferasirox sandoz | Deferasirox teva | Deferasirox zentiva | Exferana | Exjade</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Deferasipuren | Deferasirox accord | Deferasirox al | Deferasirox axiromed | Deferasirox beta | Deferasirox glenmark | Deferasirox hexal | Deferasirox holsten | Deferasirox mylan | Deferasirox ratiopharm | Deferasirox stada | Deferasirox zentiva | Exjade</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Exjade</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Deferax | Exjade | Ferasiro</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Deferasirox accord | Exjade</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Exjade | Jadenu | Rasiroxpine | Ronisirox</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Deferasirox aurovi | Deferasirox ratiopharm | Deferasirox stada | Deferasirox teva | Deferasirox viso | Exjade | Ferupantil</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Deferasirox accord | Deferasirox glenmark | Deferasirox orifarm | Exjade</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Deferasirox accord | Deferasirox biogaran | Deferasirox mylan | Deferasirox sandoz | Deferasirox teva | Deferasirox zentiva | Exjade</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Deferasirox accord | Deferasirox sandoz | Exjade</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Deferasirox accord | Exjade</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Exjade | Jadenu</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Exjade</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Deferasirox pharmascience | Deferasirox sandoz | Exferana | Exjade</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Exjade</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Deferasirox accord | Exjade</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Asunra | Defrijet | Desifer | Desirox | Ferasiro | Oleptiss</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Fuarte | Ipijade</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Deferasirox accord | Deferasirox doc | Deferasirox mylan | Deferasirox sandoz | Deferasirox zentiva | Exjade</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Difirax | Exjade</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Exjade</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Asunra</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Exjade | Hemosirox</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Exjade | Jadenu</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Difirax | Exjade | Jadenu</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Desirox | Exjade</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Deferasirox accord | Exjade</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Deferasirox accord | Exjade</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Exjade</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Exjade | Jadinu | Metikosib</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Exjade</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Asunra</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Deferasirox aurobindo | Deferasirox mylan | Deferasirox sandoz | Deferasirox teva | Deferasirox will pharma | Exjade</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Deferasirox accord | Deferasirox sandoz | Exjade</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Exjade</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Deferax | Exjade</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Exjade | Jadenu</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Arefed | Dasirox | Defox | Defrx | Desirox | Efesir | Ferochel | Obsarox | Oderox | Oleptiss | Xefra</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Exjade</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Exjade | Jadenu | Jadenu sprinkle</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Deferasirox accord | Deferasirox generis | Deferasirox mylan | Deferasirox teva | Exjade</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Deferasirox quimfa | Exjade</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Chelaton | Exjade | Fuarte | Irorest | Jadenu | Magneto</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Deferasirox accord | Exjade | Reditens | Zeoks</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Dzhadenu | Exjade | Jadenu</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Chelaton | Defirox | Exjade | Jadenu</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Deferasirox accord | Deferasirox glenmark | Deferasirox medical valley | Deferasirox mylan | Deferasirox orifarm | Deferasirox sandoz | Deferasirox stada | Deferasirox teva | Exjade</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Exjade | Jadenu</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Deferasiroks accord | Exjade</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Deferasirox accord | Deferasirox glenmark | Deferasirox mylan | Deferasirox sandoz | Deferasirox teva | Deferasirox zentiva | Exferana | Exjade</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Dejex | Jadenu</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Deferox | Difexa | Exjade</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Defejact | Defroni | Enferox | Enferox easy | Exjade | Febind | Ferout | Ferout S | Fesor | Fuarte | Fuarte neo | Oxfet | Vexperda | Zeno</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Exjade | Jadenu</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Exjade</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Fesirox | Jadenu</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Defothal | Dercifera</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Deferasirox 125 alkem | Deferasirox 250 alkem | Defkem | Exjade | Jadenu | Nujade</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Asunra</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-21705992">
<a name="21705992"></a>Anastasi S, Lisi R, Abbate G, Caruso V, Giovannini M, De Sanctis V. Absence of teratogenicity of deferasirox treatment during pregnancy in a thalassaemic patient. <i>Pediatr Endocrinol Rev.</i> 2011;8(Suppl 2):S345-S347.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferasirox-drug-information/abstract-text/21705992/pubmed" id="21705992" target="_blank">21705992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21452290">
<a name="21452290"></a>Bacon BR, Adams PC, Kowdley KV, et al, “Diagnosis and Management of Hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Disease,” <i>Hepatology</i>, 2011, 54(1):328-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferasirox-drug-information/abstract-text/21452290/pubmed" id="21452290" target="_blank">21452290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21628399">
<a name="21628399"></a>Cappellini MD, Bejaoui M, Agaoglu L, et al, "Iron Chelation With Deferasirox in Adult and Pediatric Patients With Thalassemia Major: Efficacy and Safety During 5 Years' Follow-Up," <i>Blood</i>, 2011, 118(4):884-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferasirox-drug-information/abstract-text/21628399/pubmed" id="21628399" target="_blank">21628399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16352812">
<a name="16352812"></a>Cappellini MD, Cohen A, Piga A, et al, “A Phase 3 Study of Deferasirox (ICL670), a Once-Daily Oral Iron Chelator, in Patients With Beta-Thalassemia,”<i> Blood</i>, 2006, 107(9):3455-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferasirox-drug-information/abstract-text/16352812/pubmed" id="16352812" target="_blank">16352812</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19059055">
<a name="19059055"></a>Cappellini MD, “Long-Term Efficacy and Safety of Deferasirox,” <i>Blood Rev</i>, 2008, 22(Suppl 2):35-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferasirox-drug-information/abstract-text/19059055/pubmed" id="19059055" target="_blank">19059055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17951527">
<a name="17951527"></a>Cohen AR, Glimm E, and Porter JB, “Effect of Transfusional Iron Intake on Response to Chelation Therapy in β-Thalassemia Major,” <i>Blood</i>, 2008, 111(2):583-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferasirox-drug-information/abstract-text/17951527/pubmed" id="17951527" target="_blank">17951527</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26861970">
<a name="26861970"></a>Diamantidis MD, Neokleous N, Agapidou A, et al. Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic?<i> Int J Hematol.</i> 2016;103(5):537-544. doi: 10.1007/s12185-016-1945-y.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferasirox-drug-information/abstract-text/26861970/pubmed" id="26861970" target="_blank">26861970</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Exjade.1">
<a name="Exjade.1"></a>Exjade (deferasirox) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Exjade.2">
<a name="Exjade.2"></a>Exjade (deferasirox) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28992618">
<a name="28992618"></a>Fozza C, Asara MA, Vacca N, et al. Pregnancy outcome among women with beta-thalassemia major in north Sardinia. <i>Acta Haematol.</i> 2017;138(3):166-167. doi: 10.1159/000480450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferasirox-drug-information/abstract-text/28992618/pubmed" id="28992618" target="_blank">28992618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12817519">
<a name="12817519"></a>Galanello R, Piga A, Alberti D, et al, "Safety, Tolerability, and Pharmacokinetics of ICL670, a New Orally Active Iron-Chelating Agent in Patients With Transfusion-Dependent Iron Overload Due to Beta-Thalassemia," <i>J Clin Pharmacol</i>, 2003, 43(6):565-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferasirox-drug-information/abstract-text/12817519/pubmed" id="12817519" target="_blank">12817519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29719999">
<a name="29719999"></a>Giampreti A, Mattioli F, Faraoni L et al. Lactation in beta-thalassemia major: Is deferasirox compatible? The first case with clinical data and breastmilk concentrations. Abstract. 38th International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) 22-25 May 2018, Bucharest, Romania [published correction appears in <i>Clin Toxicol (Phila).</i> 2018;56(9):872]. <i>Clin Toxicol (Phila)</i>. 2018;56(6):539.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferasirox-drug-information/abstract-text/29719999/pubmed" id="29719999" target="_blank">29719999</a>]</span>
<span class="doi">10.1080/15563650.2018.1457818</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22919029">
<a name="22919029"></a>Hoffbrand AV, Taher A, and Cappellini MD, “How I Treat Transfusional Iron Overload,” <i>Blood</i>, 2012, 120(18):3657-69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferasirox-drug-information/abstract-text/22919029/pubmed" id="22919029" target="_blank">22919029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jadenu.1">
<a name="Jadenu.1"></a>Jadenu (deferasirox) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jadenu.2">
<a name="Jadenu.2"></a>Jadenu (deferasirox) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23669734">
<a name="23669734"></a>Ktena YP, Athanasiadou A, Lambrou G, et al, “Iron Chelation With Deferasirox for the Treatment of Secondary Hemosiderosis in Pediatric Oncology Patients: A Single-center Experience,” <i>J Pediatr Hematol Oncol</i>, 2013 [epub ahead of print].<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferasirox-drug-information/abstract-text/23669734/pubmed" id="23669734" target="_blank">23669734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22547607">
<a name="22547607"></a>List AF, Baer MR, Steensma DP, et al, "Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion-Dependent Patients With Myelodysplastic Syndrome," <i>J Clin Oncol</i>, 2012, 30(17):2134-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferasirox-drug-information/abstract-text/22547607/pubmed" id="22547607" target="_blank">22547607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12747879">
<a name="12747879"></a>Nisbet-Brown E, Oliveri NF, Giardina PJ, et al, "Effectiveness and Safety of ICL670 in Iron-Loaded Patients With Thalassaemia: A Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation Trial," <i>Lancet</i>, 2003, 361(9369):1597-602.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferasirox-drug-information/abstract-text/12747879/pubmed" id="12747879" target="_blank">12747879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19996412">
<a name="19996412"></a>Pennell DJ, Porter JB, Cappellini MD, et al, “Efficacy of Deferasirox in Reducing and Preventing Cardiac Iron Overload in Beta-Thalassemia,” <i>Blood</i>, 2010, 115(12):2364-71.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferasirox-drug-information/abstract-text/19996412/pubmed" id="19996412" target="_blank">19996412</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20814896">
<a name="20814896"></a>Phatak P, Brissot P, Wurster M, et al. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. <i>Hepatology</i>. 2010;52(5):1671-1779.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferasirox-drug-information/abstract-text/20814896/pubmed" id="20814896" target="_blank">20814896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20116637">
<a name="20116637"></a>Porter JB, “Optimizing Iron Chelation Strategies In Beta-Thalassaemia Major,” <i>Blood Rev</i>, 2009, 23(Suppl 1):3-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferasirox-drug-information/abstract-text/20116637/pubmed" id="20116637" target="_blank">20116637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18028431">
<a name="18028431"></a>Porter J, Galanello R, Saglio G, et al, “Relative Response of Patients With Myelodysplastic Syndromes and Other Transfusion-Dependent Anaemias to Deferasirox (ICL670): A 1-Yr Prospective Study,” <i>Eur J Haematol</i>, 2008, 80(2):168-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferasirox-drug-information/abstract-text/18028431/pubmed" id="18028431" target="_blank">18028431</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21813448">
<a name="21813448"></a>Rachmilewitz EA and Giardina PJ, “How I Treat Thalassemia,” <i>Blood</i>, 2011, 118(13):3479-88.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferasirox-drug-information/abstract-text/21813448/pubmed" id="21813448" target="_blank">21813448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19148949">
<a name="19148949"></a>Raphael JL, Bernhardt MB, Mahoney DH, et al, “Oral Iron Chelation and the Treatment of Iron Overload in a Pediatric Hematology Center,” <i>Pediatr Blood Cancer</i>, 2009, 52(5):616-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferasirox-drug-information/abstract-text/19148949/pubmed" id="19148949" target="_blank">19148949</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21273766">
<a name="21273766"></a>Ricchi P, Costantini S, Spasiano A, Di Matola T, Cinque P, Prossomariti L. A case of well-tolerated and safe deferasirox administration during the first trimester of a spontaneous pregnancy in an advanced maternal age thalassemic patient. <i>Acta Haematol</i>. 2011;125(4):222-224. doi: 10.1159/000323289.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferasirox-drug-information/abstract-text/21273766/pubmed" id="21273766" target="_blank">21273766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16162884">
<a name="16162884"></a>Rund D and Rachmilewitz E, "Beta-Thalassemia," <i>N Engl J Med</i>, 2005, 353(11):1135-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferasirox-drug-information/abstract-text/16162884/pubmed" id="16162884" target="_blank">16162884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18218291">
<a name="18218291"></a>Séchaud R, Dutreix C, Balez S, et al, “Relative Bioavailability of Deferasirox Tablets Administered Without Dispersion and Dispersed in Various Drinks,” <i>Int J Clin Pharmacol Ther</i>, 2008, 46(2):102-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferasirox-drug-information/abstract-text/18218291/pubmed" id="18218291" target="_blank">18218291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22589472">
<a name="22589472"></a>Taher AT, Porter J, Viprakasit V, et al, “Deferasirox Reduces Iron Overload Significantly in Nontransfusion-Dependent Thalassemia: 1-Year Results From a Prospective, Randomized, Double-Blind, Placebo-Controlled Study,” <i>Blood</i>, 2012, 120(5):970-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferasirox-drug-information/abstract-text/22589472/pubmed" id="22589472" target="_blank">22589472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17233848">
<a name="17233848"></a>Vichinsky E, Onyekwere O, Porter J, et al. A Randomised Comparison of Deferasirox Versus Deferoxamine for the Treatment of Transfusional Iron Overload in Sickle Cell Disease. <i>Br J Haematol</i>. 2007;136(3):501-508.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferasirox-drug-information/abstract-text/17233848/pubmed" id="17233848" target="_blank">17233848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21198860">
<a name="21198860"></a>Vini D, Servos P, Drosou M. Normal pregnancy in a patient with β-thalassaemia major receiving iron chelation therapy with deferasirox (Exjade®). Eur J Haematol. 2011 Mar;86(3):274-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferasirox-drug-information/abstract-text/21198860/pubmed" id="21198860" target="_blank">21198860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18534729">
<a name="18534729"></a>Yusuf B, McPhedran P, and Brewster UC, “Hypocalcemia in a Dialysis Patient Treated With Deferasirox for Iron Overload,” <i>Am J Kidney Dis</i>, 2008, 52(3):587-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferasirox-drug-information/abstract-text/18534729/pubmed" id="18534729" target="_blank">18534729</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8794 Version 429.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
